Literature DB >> 24310500

Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients.

Emmanouela Sarchianaki1, Stavros P Derdas, Markos Ntaoukakis, Elena Vakonaki, Eleni D Lagoudaki, Ismini Lasithiotaki, Anna Sarchianaki, Anastasios Koutsopoulos, Emmanouil K Symvoulakis, Demetrios A Spandidos, Katerina M Antoniou, George Sourvinos.   

Abstract

Although the role of human papillomavirus (HPV) in the development of uterine cervical cancer is well established, the role of HPV in lung carcinogenesis remains controversial. The detection rates of HPV DNA are subject to a wide variation from 0 to 100%. This is partly influenced by the detection techniques employed. To elucidate the impact of HPV infection on lung parenchyma, we analyzed 100 non-small cell lung cancer (NSCLC) specimens (39 squamous cell carcinomas, 50 adenocarcinomas, 5 samples with characteristics of both squamous cell and adenocarcinoma, 5 undifferentiated and 1 large cell carcinoma) from the region of Crete, Greece. Sixteen non-cancerous samples served as the negative controls. DNA was extracted from 100 paraffin-embedded tissue sections obtained from NSCLC patients. The specimens were examined for the detection of HPV DNA by Real-Time PCR using GP5+/GP6+ primers. Furthermore, the HPV-positive samples were subjected to genotyping. In contrast to the absence of viral genomes in the control samples, HPV DNA was detected in 19 NSCLC specimens (19%). In particular, 4 squamous cell carcinomas, 12 adenocarcinomas, 1 sample with characteristics of both squamous cell and adenocarcinoma, and 2 undifferentiated samples were HPV-positive. The distribution of HPV genotypes was as follows: HPV 16: eight cases (42.1%); HPV 11: three cases (15.8%); HPV 6: one case (5.2%); HPV 59: one case (5.2%); HPV 33: two cases (10.5%); HPV 31: two cases (10.5%) and HPV 18: two cases (10.5%). The presence of HPV in the tumor samples provides evidence of the potential role of HPV in NSCLC and strongly argues for additional research on this issue.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24310500     DOI: 10.1007/s13277-013-1419-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  Molecular pathological findings of Merkel cell polyomavirus in lung cancer: a possible etiopathogenetic link?

Authors:  Katerina M Antoniou; Ismini Lasithiotaki; Emmanouil Symvoulakis; Stavros P Derdas; Anna Psaraki; Demetrios A Spandidos; Efstathios N Stathopoulos; Nikolaos M Siafakas; George Sourvinos
Journal:  Int J Cancer       Date:  2013-06-29       Impact factor: 7.396

Review 2.  Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer.

Authors:  J Viallet; J D Minna
Journal:  Am J Respir Cell Mol Biol       Date:  1990-03       Impact factor: 6.914

3.  EGFR mutations and human papillomavirus in lung cancer.

Authors:  Takuya Kato; Chihaya Koriyama; Noureen Khan; Takuya Samukawa; Masakazu Yanagi; Tsutomu Hamada; Naoya Yokomakura; Takeshi Otsuka; Hiromasa Inoue; Masami Sato; Shoji Natsugoe; Suminori Akiba
Journal:  Lung Cancer       Date:  2012-09-10       Impact factor: 5.705

4.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

5.  Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas.

Authors:  Michihiro Baba; Andres Castillo; Chihaya Koriyama; Masakazu Yanagi; Hidehiko Matsumoto; Shoji Natsugoe; Karem Y Shuyama; Noureen Khan; Michiyo Higashi; Tetsuhiko Itoh; Yoshito Eizuru; Takashi Aikou; Suminori Akiba
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

Review 6.  HPV testing in cervical screening.

Authors:  Antoinette A T P Brink; Peter J F Snijders; Chris J L M Meijer; Johannes Berkhof; René H M Verheijen
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2005-12-13       Impact factor: 5.237

7.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

8.  The presence of Merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl-2 genes in non-small cell lung cancer.

Authors:  I Lasithiotaki; K M Antoniou; S P Derdas; E Sarchianaki; E K Symvoulakis; A Psaraki; D A Spandidos; E N Stathopoulos; N M Siafakas; G Sourvinos
Journal:  Int J Cancer       Date:  2013-02-27       Impact factor: 7.396

9.  Human papillomavirus type 16 and 18 infection is associated with lung cancer patients from the central part of China.

Authors:  Yongping Wang; Aifeng Wang; Rui Jiang; Huaxiong Pan; Bangxing Huang; Yan Lu; Cuihuan Wu
Journal:  Oncol Rep       Date:  2008-08       Impact factor: 3.906

10.  The prevalence of human papillomavirus infection in Korean non-small cell lung cancer patients.

Authors:  Moo Suk Park; Yoon Soo Chang; Ju Hye Shin; Dae Joon Kim; Kyung Young Chung; Dong Hwan Shin; Jin Wook Moon; Shin Myung Kang; Chang Hoon Hahn; Young Sam Kim; Joon Chang; Sung Kyu Kim; Se Kyu Kim
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

View more
  16 in total

Review 1.  Human papillomavirus and lung cancinogenesis: an overview.

Authors:  Antonio Carlos de Freitas; Ana Pavla Gurgel; Elyda Golçalves de Lima; Bianca de França São Marcos; Carolina Maria Medeiros do Amaral
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-29       Impact factor: 4.553

2.  Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development.

Authors:  Yan Yu; Xiaofei Liu; Yuxuan Yang; Xiaodan Zhao; Jianjun Xue; Weixiao Zhang; Aimin Yang
Journal:  Oncol Lett       Date:  2015-05-15       Impact factor: 2.967

3.  Association between human papillomavirus and EGFR mutations in advanced lung adenocarcinoma.

Authors:  Ming Li; Fang Deng; Li-Ting Qian; Shui-Ping Meng; Yang Zhang; Wu-Lin Shan; Xiao-Lei Zhang; Bao-Long Wang
Journal:  Oncol Lett       Date:  2016-07-12       Impact factor: 2.967

4.  Correlation between squamous cell carcinoma of the lung and human papillomavirus infection and the relationship to expression of p53 and p16.

Authors:  Xiaohong Fan; Keke Yu; Jie Wu; Jinchen Shao; Lei Zhu; Jie Zhang
Journal:  Tumour Biol       Date:  2014-12-28

5.  Cystatin E/M Suppresses Tumor Cell Growth through Cytoplasmic Retention of NF-κB.

Authors:  Hendrick Soh; Natarajan Venkatesan; Mysore S Veena; Sandhiya Ravichandran; Alborz Zinabadi; Saroj K Basak; Kislay Parvatiyar; Meera Srivastava; Li-Jung Liang; David W Gjertson; Jorge Z Torres; Neda A Moatamed; Eri S Srivatsan
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

6.  The association between human papillomavirus infection and lung cancer: a system review and meta-analysis.

Authors:  Wei-Min Xiong; Qiu-Ping Xu; Xu Li; Ren-Dong Xiao; Lin Cai; Fei He
Journal:  Oncotarget       Date:  2017-10-09

7.  Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer.

Authors:  Ausra Stumbryte; Zivile Gudleviciene; Gabrielis Kundrotas; Daiva Dabkeviciene; Agne Kunickaite; Saulius Cicenas
Journal:  Oncotarget       Date:  2017-11-29

8.  The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer.

Authors:  Hengrui Liang; Zhenkui Pan; Xiuyu Cai; Wei Wang; Chengye Guo; Jiaxi He; Yuehan Chen; Zhichao Liu; Bo Wang; Jianxing He; Wenhua Liang
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 9.  An updated overview of HPV-associated head and neck carcinomas.

Authors:  Apostolos Zaravinos
Journal:  Oncotarget       Date:  2014-06-30

Review 10.  Human papillomavirus infection and risk of lung cancer in never-smokers and women: an 'adaptive' meta-analysis.

Authors:  Jong-Myon Bae; Eun Hee Kim
Journal:  Epidemiol Health       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.